Echocardiographic assessment of tricuspid regurgitation and pericardial effusion after cardiac device implantation by Wiechecka, Katarzyna et al.
Address for correspondence: Agnieszka Kapłon-Cieślicka, MD, PhD, 1st Chair and Department of Cardiology, Medical  
University of Warsaw, Public Central Teaching Hospital in Warsaw, ul. Banacha 1a, 02–097 Warszawa, Poland,  
tel: +48 22 599 29 58, fax: +48 22 599 19 57, e-mail: agnieszka.kaplon-cieslicka@wum.edu.pl
Received: 28.10.2018 Accepted: 31.03.2019
Echocardiographic assessment of tricuspid  
regurgitation and pericardial effusion  
after cardiac device implantation
Katarzyna Wiechecka, Bartosz Wiechecki, Agnieszka Kapłon-Cieślicka, Agata Tymińska, 
Monika Budnik, Dominika Hołowaty, Krzysztof Jakubowski, Marcin Michalak,  
Elżbieta Świętoń, Przemysław Stolarz, Roman Steckiewicz, Marcin Grabowski,  
Piotr Scisło, Janusz Kochanowski, Krzysztof J. Filipiak, Grzegorz Opolski
1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
Abstract
Background: The frequency of cardiac implantable electronic device (CIED) implantations is con-
stantly increasing. Pericardial effusion (PE) and tricuspid regurgitation (TR) may occur after CIED 
implantation. The aim of the present study is to evaluate the prevalence and risk factors for new occur-
rences or progression of TR and PE early after CIED implantation.
Methods: This is an on-going, single-center, observational study of patients after their first CIED im-
plantation, with an echocardiographic evaluation within 60 days before and 7 days after the procedure. 
Data are presented for first 110 consecutive patients who underwent CIED implantation from August 
2015 to July 2016. 
Results: Median age was 75 years, and 44% were women. In total, 87 (79%) pacemakers, 21 (19%) 
implantable cardioverter-defibrillators and 2 cardiac resynchronization therapy devices were implanted. 
After CIED implantation, there was TR progression in 17 (16%) patients: 5 patients developed mod-
erate TR, none developed severe TR. An increase in TR was more often observed after implantations 
performed by operators in training than by certified operators (35% vs. 12%, p = 0.02). New PE after 
the procedure was observed in 8 (7%) patients and was trivial (< 5 mm) in all cases. Patients with new 
PE after implantation had lower baseline hemoglobin levels and tended to be women.
Conclusions: New PE and an increase in TR severity are rare complications early after CIED im-
plantation. Operator experience might be related to TR progression. Increasing the number of patients 
in the current on-going study will allow a more reliable assessment of the prevalence and risk factors of 
these complications. (Cardiol J XXXX; XX, X: xx–xx)
Key words: cardiac implantable electronic device, pacemaker, implantable cardioverter-
-defibrillator, complications 
Introduction
Since the first pacemaker implantation in 
1958, the number of cardiac implantable electronic 
devices (CIEDs): permanent pacemakers (PPMs), 
implantable cardioverter-defibrillators (ICDs) and 
cardiac resynchronization therapy (CRT) has been 
constantly rising [1]. According to a report from 
the European Heart Rhythm Association, 500,411 
PPMs, 85,289 ICDs and 51,274 CRTs were im-
planted in European Society of Cardiology (ESC) 
countries in 2013 [2]. Although CIED implanta-
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tion is considered a relatively low-risk procedure, 
especially if performed in specialized centers, it 
can lead to some early and late complications [3]. 
Discovering tricuspid valve leaflet perforation 
at an autopsy in 1974 was the first described case 
of right ventricle (RV) lead-associated tricuspid 
regurgitation (TR) [4]. In general, in most cases, 
TR is secondary to increased pulmonary and RV 
pressure resulting in RV and tricuspid annular 
dilatation; less often it is the result of primary 
leaflet pathology [5]. In the Framingham Heart 
Study, the prevalence of moderate to severe TR 
increased with age, reaching up to 1.5% and 5.6%, 
respectively, in men and women aged 70 years and 
more [6]. Due to a lack of prospective studies, the 
incidence of hemodynamically significant TR after 
CIED implantation is difficult to estimate, however, 
in a retrospective, case-control study conducted 
by Paniagua et al. [7] in a large echocardiography 
database, the prevalence of moderate to severe 
TR in patients with transvenous PPM leads was 
twice as high as in the control group. Depending on 
time after RV lead implantation, TR can be caused 
by mechanical interference or lead-related leaflet 
fibrosis. Mechanical mechanism occurs earlier and 
includes adherence, impingement of electrodes to 
tricuspid leaflets or laceration and rarely perfora-
tion of valve apparatus, while lead-related fibrosis 
appears over time after implantation [8, 9]. The 
relation between tricuspid leaflets and pacing lead 
might also be crucial in cases of future transvenous 
lead extraction, which is a complex surgical pro-
cedure itself and might cause or increase TR [10]. 
TR may also occur as a result of atrioventricular 
dyssynchrony, specifically in ventricular pacing [11]. 
To avoid future TR after lead implantation some au-
thors suggest only left ventricular lead stimulation 
especially in patients with either prosthetic tricuspid 
valve, annulus or baseline severe TR [12]. Regard-
less of the mechanism, implantation-induced TR is 
associated with worse prognosis [13, 14]. However, 
the exact incidence of implantation-induced TR in a 
modern series is to be determined, as previous stud-
ies usually only included small numbers of patients 
or were limited by lack of baseline echocardiographic 
assessment [15–17].
Rarely, CIED implantation procedures may 
be complicated by pericardial effusion (PE) and 
tamponade, with a prevalence of approximately 
2% and 0.6%, respectively [18]. These complica-
tions can lead to prolonged hospital stay and higher 
costs [3, 18].
The aim of the present study is to evaluate 
the prevalence and progression of TR and PE early 
after CIED implantation, and to determine risk fac-
tors for the development of these complications. 
This article presents the design of the current 
study, as well as preliminary results based on data 
from the first 110 patients.  
Methods 
Study population
In this single-center, observational, retrospec-
tive study, analyses data are presented from 400 
consecutive patients after first CIED implantation 
(PPM, ICD or CRT), who had echocardiographic 
assessment of TR and PE before and after the proce-
dure. Only patients with echocardiogram performed 
less than 60 days before and up to 7 days after 
implantation are included in the study. So far, 110 
patients, who underwent device implantation from 
August 2015 to July 2016, were included in the study.
Data collection
In the study, data on baseline clinical charac-
teristics, results of diagnostic tests performed, and 
pharmacotherapy (including antithrombotic treat-
ment) are collected retrospectively from medical 
records. Data on CIED implantation include: type 
of device, number of leads, localization of leads, 
device manufacturer, operator, and information 
on complications (occurrence or progression of 
TR, occurrence of PE, pneumothorax, or other 
complications). Five different physician operators 
performed the CIEDs implantation: operators 1, 
3 and 5 are certified operators with more than 
10 years experience in CIED implantation, while 
operators 2 and 4 were, at the time of the procedure 
performed, operators in training with experience 
of less than or equal to 5 years.
Echocardiographic assessment
All patients included in this study had two-
dimensional transthoracic echocardiogram per-
formed, before and after the procedure. In the 
documented department, echocardiographic as-
sessment following CIED implantation is rou-
tinely performed within 7 days in all patients, as 
a standard of care, usually on the first day after 
the procedure, regardless of the patient’s clinical 
condition. Only patients with available pre- and 
post-implantation transthoracic echocardiography 
results with assessment of both PE and TR were 
included in the study. Echocardiograms are per-
formed in the Department’s Echocardiography 
Laboratory (certified with grade C accreditation 
of the Section of Echocardiography of the Polish 
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Cardiac Society), using Philips iE33 or Philips 
EPIQ 7 Ultrasound Machines (Philips Medical 
Systems, Andover, Massachusetts, USA) by quali-
fied echocardiographers. Presence of PE and TR 
severity are analyzed using all standard views, 
including parasternal, apical and subcostal views. 
TR is graded as trivial/mild, moderate and severe 
according to the current European Association of 
Cardiovascular Imaging (EACVI) guidelines [19]. 
PE is graded as trivial (< 5 mm), mild (≥ 5 and < 
10 mm), moderate (10–20 mm) and large (> 20 
mm) according to ESC guidelines [20]. 
In the study, TR is described either as newly 
developed (if no TR was present before the pro-
cedure) or as TR progression 1) from trivial/mild 
to moderate, 2) from moderate to severe, 3) from 
trivial/mild to severe, or as a decrease in TR sever-
ity. Similarly, PE is reported as newly developed 
or as an increase in the amount of fluid after the 
procedure.
Clinical endpoints
Primary endpoints include: 1) occurrence or 
progression of TR, and 2) occurrence or progres-
sion of PE after first CIED implantation.
Statistical analysis
Statistical analyses were performed using 
SPSS software, version 22 (IBM SPSS Statistics 
22, New York, USA). Normally distributed continu-
ous variables were presented as mean values and 
standard deviations, while ordinal variables and non-
normally distributed continuous variables as median 
values and interquartile ranges (IQR). Categorical 
data were presented as percentages. The significance 
of differences between groups was determined by 
the Fisher exact test for categorical variables and the 
Mann-Whitney U test for continuous and ordinal vari-
ables respectively. P-value of ≤ 0.05 was considered 
significant. All tests were two-tailed.
Results 
From August 2015 to July 2016, 110 patients 
after their first CIED implantation were included in 
the study. Figure 1 shows flow-chart of patient in-
clusion in the study and types of devices implanted. 
Median age of the study group was 75.1 years and 
44% were female. Hypertension was present in 
77% of patients, coronary artery disease — in 37%, 
heart failure — in 45%, and atrial fibrillation — in 
56%. Table 1 presents baseline clinical character-
istics of the study group.
Pre- and post-interventional TR prevalence 
is shown in Figure 2. Change in TR severity after 
the procedure was observed in 34 (31%) patients, 
including 17 (16%) patients with TR worsening 
and 17 (16%) patients with TR improvement, as 
462 CIED implantations
307 rst CIED implantations
110 patients included in the analysis
2 CRTs
(1.8%)
21 ICDs
(19%)
16 ICD-VR
(15%)
87 PPMs
(79%)
59 DDD
(54%)
28 VVI
(26%)
5 ICD-DR
(4.5%)
197 patients with missing
echocardiographic data:
— 169 with missing data on TTE within
 60 days before the procedure
— 23 with missing data on TTE within
 7 days after the procedure*
— 5 with missing both TTE results
Figure 1. Flow-chart of patient inclusion in the study and types of devices implanted from August 2015 to July 2016; 
*missing data on tricuspid regurgitation after cardiac implantable electronic device (CIED) implantation; CRT — car-
diac resynchronization therapy; ICD — implantable cardioverter-defibrillator; ICD-VR — single-chamber cardioverter-
defibrillator; ICD-DR — dual-chamber cardioverter-defibrillator; PPM —  permanent pacemaker; DDD — dual-chamber 
pacemaker; VVI — ventricular single-chamber pacemaker; TTE — transthoracic echocardiography.
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Table 1. Baseline characteristics of the study population and comparison of patients with and without 
an increase in tricuspid regurgitation (TR) after cardiac device implantation.
Variable Study population 
(n = 110)
With an increase 
in TR (n = 17)
Without an  
increase in TR  
(n = 93)
P
Age [years] 75.1 (69.0–84.0) 70.0 (65.0–84.5) 79.0 (69.0–84.0) 0.46
Female gender 44% 59% 41% 0.19
BMI [kg/m2] 27.9 (24.1–30.7);  
n = 91
28.1 (23.4–29.8);  
n = 11
27.7 (24.1–30.8);  
n = 80
0.97
Comorbidities
Hypertension 77% 76% 77% 1.00
Coronary artery disease 37% 35% 38% 1.00
Previous MI 18% 12% 19% 0.73
Prior PCI 19% 12% 20% 0.52
Prior CABG 7.3% 0% 8.6% 0.35
Heart failure 45% 47% 44% 1.00
Atrial fibrillation: 56% 41% 58% 0.29
Paroxysmal 29% 24% 30% 0.77
Persistent 5.5% 5.9% 5.4% 1.00
Permanent 21% 12% 23% 0.52
Diabetes 26% 18% 27% 0.55
Obesity 32% 27% 33% 0.56
Hyperlipidemia 67% 82% 65% 0.26
Current or former smoking 33% 29% 33% 1.00
Pharmacotherapy
Anticoagulation: 67% 53% 70% 0.17
Rivaroxaban 20% 30% 18% 0.50
Dabigatran 6.4% 0% 7.5% 0.59
Vitamin K antagonist 19% 12% 20% 0.50
LMWH as bridging therapy 31% 24% 33% 0.38
Single antiplatelet therapy 26% 18% 27% 0.55
Dual antiplatelet therapy 3.6% 5.9% 3.2% 0.49
Diuretics 73% 65% 75% 0.38
Laboratory findings 
Hemoglobin [g/dL] 13.0 (12.0–14.0) 13.0 (12.0–14.4) 13.0 (12.0–14.0) 0.97
WBC count [103/mm3] 7.1 (5.9–8.5) 6.5 (5.7–8.6) 7.2 (5.9–8.6) 0.60
Platelets [103/mm3] 205 (156–243) 223 (193–243) 202 (149–245) 0.14
Serum creatinine [mg/dL] 1.12 (0.91–1.36) 0.96 (0.87–1.20) 1.17 (0.92–1.39) 0.21
eGFR [mL/min/1.73 m2] 56 (45–60) 60 (44–60) 55 (45–60) 0.32
CRP [mg/L] 2.35 (1.3–7.0);  
n = 100
3.1 (1.3–7.2);  
n = 15
2.2 (1.2–5.6);  
n = 85
0.50
NT-proBNP [pg/mL] 1123 (482–2313);  
n = 78
1464 (523–2646);  
n = 13
991 (464–2238);  
n = 65
0.62
INR 1.1 (1.0–1.2);  
n = 104
1.1 (1.0–1.1);  
n = 15
1.1 (1.0–1.2);  
n = 89
0.72
APTT [s] 30.9 (27.4–35.8);  
n = 98
31.5 (28.0–36.8);  
n = 14
30.9 (27.2–35.6);  
n = 84
0.68
APTT — activated partial thromboplastin time; BMI — body mass index; CABG — coronary artery bypass grafting; CRP — C-reactive protein; 
eGFR — estimated glomerular filtration rate; INR — international normalized ratio; LMWH — low-molecular weight heparin; MI — myocardial 
infarction; NT-proBNP — N-terminal pro-B-type natriuretic peptide; PCI — percutaneous coronary intervention; PT — prothrombin time;  
WBC — white blood cell
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presented in Figure 2. Comparison of patients with 
and without an increase in TR after the procedure 
is presented in Tables 1 and 2. In the present study, 
newly developed TR and/or TR progression was 
more often observed after implantations performed 
by operators in training than after procedures ex-
ecuted by certified operators (35% vs. 12%, p = 
0.02), as shown in Table 3. 
None of the patients had any PE before the 
procedure. PE after the procedure was observed 
in 8 of 110 patients (7.3%) and only trivial (< 5 
mm) amounts were found. Comparisons of patients 
with and without PE after the procedure is shown 
in Tables 4 and 5. Patients who developed PE after 
CIED implantation had lower baseline hemoglobin 
concentration. There was a tendency for women 
to develop PE more often.
No cases of pneumothorax nor other severe 
complications were observed early after CIED 
implantation in the study group.
Discussion
The preliminary results of the current study 
suggest that newly developed TR or worsening 
of TR early after CIED implantation was not very 
common (16% of patients) and was, in most cases, 
not hemodynamically significant (at least initially), 
as none of the patients developed severe TR and 
only 5 (4.5%) patients developed moderate TR. 
However, these observations were made early 
after CIED implantation, and it is difficult to pre-
dict further TR progression and its implications 
in long-term follow-up in these patients. Previous 
studies did not yield consistent results, mostly be-
cause they were retrospective analyses conducted 
in small patient cohorts, allowing only a rough 
estimation of post-implantation TR incidence. 
The present findings are similar to the results of a 
study by Rothschild et al. [15] on small population 
(n = 36), where 6 (17%) patients developed an 
immediate increase in TR grade post-implantation, 
nevertheless, there was no progression to moder-
ate or severe TR in any of the patients. However, 
after a median of 113 days, Klutstein et al. [21] 
reported worsening of TR by more than 2 grades in 
18% of patients with pre-procedural TR described 
as less than moderate. On the contrary, Webster 
et al. [22] studied a population of 123 patients at 
a median age of 16 years at the time of RV-lead 
placement, and reported no TR worsening 8 months 
after implantation and only modest TR increase 
(from 1.54 to 1.69 on a scale from 0 to 4) after over 
2 years. The discrepancy in results between stud-
ies may be partially explained by different time 
frames of post-procedure TR evaluation, as me-
chanical component of lead-related TR worsening 
appears earlier than fibrosis and scarring of valve 
apparatus. In the present study, prevalence of new 
TR development/TR progression in patients after 
procedure differed between the operators and 
was higher after implantation performed by those 
less experienced. These findings suggest that the 
experience of the operator may have significant 
impact on developing TR regurgitation after the 
procedure.
Another risk factor for CIED-related TR 
might be the number of implanted leads. Postaci 
Figure 2. Pre- and post-interventional prevalence of tricuspid regurgitation (TR) in the study group.
0%
Absent
Pre-implantation
Post-implantation
12%
1.8%
54%
74%
32%
23%
2.7%
1.8%
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n = 
n = 59
n = 81
n = 16* n = 1 n = 3 n = 2n = 2
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*
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et al. [23] observed that 9% of 32 patients with 
one ventricular lead and 56% of 18 patients with 
two ventricular leads developed severe TR. In 
the current study, only the first CIED implanta-
tions are analyzed, and thus the study does not 
include patients with previously implanted ven-
tricular leads in whom a second ventricular lead 
(e.g. defibrillation lead) is placed. Al-Bawardy 
et al. [24] studied a group of 1596 patients who 
underwent CIED implantation, with a median 
follow-up of 10 months. Most patients (61%) had 
2 leads implanted, 20% had 3 leads implanted. The 
authors concluded that the type of cardiac device 
is not related to TR worsening. In contrast, Kim 
et al. [25] reported that TR worsening was more 
common after ICD than PPM implantation (32% 
vs. 21%, p = 0.048). In the present study, ICD 
implantation was not associated with elevated 
risk for TR worsening. Increasing the number 
of patients in the current study would have al-
Table 2. Comparison of patients with and without an increase in tricuspid regurgitation (TR) after  
cardiac device implantation — procedure-related variables.
Variable With an increase in TR  
(n = 17)
Without an increase in TR  
(n = 93)
P
Cardiac device type
DDD 71%; 12/17 51%; 47/93 0.19
VVI 12%; 2/17 28%; 26/93 0.23
ICD 18%; 3/17 19%; 18/93 1.00
CRT 0%; 0/17 2.2%; 2/93 1.00
Number of leads
1 29%; 5/17 42%; 39/93 0.42
2 71%; 12/17 56%; 52/93 0.30
3 0%; 0/17 2.2%; 2/93 1.00
Type/localization of lead
Atrial 71%; 12/17 58%; 54/93 0.42
Ventricular for stimulation 82%; 14/17 79%; 73/93 1.00
Ventricular for defibrillation 18%; 3/17 22%; 20/93 1.00
Manufacturer
Biotronik 65%; 11/17 51%; 47/93 0.50
Medtronic 35%; 6/17 32%; 30/93 0.80
St. Jude Medical 0%; 0/17 17%; 16/93 0.13
Operator 0.051
Operator no. 1 0%; 0/13* 100%; 13/13*
Operator no. 2 27%; 3/11* 73%; 8/11*
Operator no. 3 11%; 3/27* 89%; 24/27*
Operator no. 4 50%; 3/6* 50%; 3/6*
Operator no. 5 15%; 8/53* 85%; 45/53*
*Refers to the number of procedures performed by the given operator; DDD — dual-chamber pacemaker; CRT — cardiac resynchronization 
therapy; ICD — implantable cardioverter defibrillator; VVI — ventricular single-chamber pacemaker
Table 3. Changes in tricuspid regurgitation (TR) severity after procedures performed by certified opera-
tors and operators in training.
Post-procedural  
changes in TR
Certified operators* 
(93 procedures)
Operators in training** 
(17 procedures)
P
Increase in TR 12%; 11/93 35%; 6/17 0.02
No change in TR 70%; 65/93 65%; 11/17 0.78
Decrease in TR 18%; 17/93 0%; 0/17 0.07
*Operators 1, 3, and 5; **operators 2 and 4
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lowed establishing whether the number and type 
of implanted leads is related to the risk of TR 
development or worsening.
Some data suggest that the technique of echo-
cardiographic evaluation of post-procedural TR 
may also affect the results. In one retrospective 
Table 4. Comparison of patients with and without pericardial effusion after cardiac device implantation 
— clinical and laboratory variables. 
Variable With pericardial effusion  
(n = 8)
Without pericardial effusion  
(n = 102)
P
Age [years] 77.5 (68.0–83.0) 78.5 (68.8–84.0) 0.96
Female gender 75% 41% 0.08
BMI [kg/m2] 26.1 (24.8–34.1); n = 7 28.0 (24.0–30.8); n = 84 0.94
Comorbidities
Hypertension 75% 78% 1.00
Coronary artery disease 63% 35% 0.12
Previous MI 25% 18% 0.64
Prior PCI 25% 19% 0.65
Prior CABG 13% 6.9% 0.47
Heart failure 25% 46% 0.30
Atrial fibrillation: 50% 56% 1.00
Paroxysmal 38% 28% 0.69
Persistent 13% 4.9% 0.37
Permanent 0% 23% 0.20
Diabetes 13% 27% 0.68
Obesity 13% 33% 0.42
Hyperlipidemia 75% 67% 1.00
Current or former smoking 25% 33% 1.00
Pharmacotherapy
Anticoagulation: 63% 68% 1.00
Rivaroxaban 25% 20% 0.60
Dabigatran 13% 5.9% 0.36
Vitamin K antagonist 13% 20% 1.00
LMWH as bridging therapy 13% 33% 0.64
Single antiplatelet therapy 25% 26% 1.00
Dual antiplatelet therapy 13% 2.9% 0.26
Diuretics 75% 73% 1.00
Laboratory findings 
Hemoglobin [g/dL] 12.0 (11.7–12.8) 13.0 (12.1–14.1) 0.04
WBC count [103/mm3] 8.3 (6.3–10.1) 7.0 (5.9–8.3) 0.13
Platelets [103/mm3] 219 (169–272) 204 (151–243) 0.38
Serum creatinine [mg/dL] 1.17 (0.74–1.28) 1.10 (0.91–1.38) 0.53
eGFR [mL/min/1.73 m2] 52 (45–60) 57 (44–60) 0.80
CRP [mg/L] 5.6 (1.2–12.5) 2.3 (1.3–5.5); n = 92 0.34
NT-proBNP [pg/mL] 774 (430–5104); n = 7 1187 (559–2240); n = 71 0.97
INR 1.0 (0.99–1.1) 1.1 (1.0–1.2); n = 96 0.36
APTT [s] 30.4 (27.3–35.3); n = 7 31.0 (27.4–35.9); n = 90 0.86
APTT — activated partial thromboplastin time; BMI - body mass index; CABG — coronary artery bypass grafting; CRP — C-reactive protein; 
eGFR — estimated glomerular filtration rate; INR — international normalized ratio LMWH — low-molecular weight heparin; MI — myocardial 
infarction; NT-proBNP — N-terminal pro-B-type natriuretic peptide; PCI — percutaneous coronary intervention; PT — prothrombin time;  
WBC — white blood cell
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study, transthoracic compared to transesophageal 
echocardiography detected fewer lead-related TRs 
in patients after CIED implantation (22% vs. 45%) 
[26]. The importance of reliable TR diagnosis is 
related to unfavorable impact of hemodynami-
cally significant TR on prognosis, which results 
predominantly from its deleterious effects on RV 
dimensions and function. Other important clinical 
implications of significant TR include occurrence 
of rhythm disturbances such as atrial fibrillation 
and the need for chronic anticoagulation [27, 28].
In the present study, there was also a propor-
tion of patients with a decrease in TR severity 
after CIED implantation. This might be related to 
possible volume depletion in these patients (fasting 
before the procedure, possibly more intensive diu-
retic treatment), as functional TR is a dynamic dis-
ease, changing in response to variation in preload 
and afterload. Another possible explanation might 
be that echocardiographic visualization is usually 
impaired for a few days after CIED implantation 
due to edema of the subcutaneous tissue in left 
subclavicular region and the diminished range 
of left upper limb movement, which might result 
in an underestimation of the actual TR volume. 
Furthermore, lead-induced artifacts might have 
impaired proper assessment of TR.
Herein, consistent with previous publications, 
new post-implantation PE was a rare complication 
[18]. A trend towards higher risk of post-procedural 
PE in women was observed, which is in line with 
a study by Ohlow et al. [18], in which female gen-
der was associated with a higher incidence of any 
PE. The authors suggested this may be due to a 
thinner RV wall in women, related to a reduced 
extension of ventricular hypotrophy and lower RV 
pressure in women, as shown in population-based 
studies [21, 27]. Thinner RV walls could increase 
the risk of ventricular perforation in women [18]. 
In the same study by Ohlow et al. [18], patients 
Table 5. Comparison of patients with and without pericardial effusion after cardiac device implantation 
— procedure-related variables.
Variable With pericardial effusion  
(n = 8)
Without pericardial effusion  
(n = 102)
P
Cardiac device type
DDD 63%; 5/8 53%; 54/102 0.72
VVI 25%; 2/8 26%; 26/102 1.00
ICD 13%; 1/8 20%; 20/102 1.00
CRT 0%; 0/8 2.0%; 2/102 1.00
Number of leads
1 25%; 2/8 42%; 42/102 0.47
2 75%; 6/8 57%; 58/102 0.46
3 0%; 0/8 2.0%; 2/102 1.00
Type/localization of lead
Atrial 75%; 6/8 59%; 60/102 0.47
Ventricular for stimulation 88%; 7/8 78%; 80/102 0.70
Ventricular for defibrillation 13%; 1/8 22%; 22/102 0.70
Manufacturer
Biotronik 63%; 5/8 52%; 53/102 0.70
Medtronic 13%; 1/8 34%; 35/102 0.27
St. Jude Medical 25%; 2/8 14%; 14/102 0.35
Operator 0.52
Operator no. 1 0%; 0/13* 100%; 13/13*
Operator no. 2 0%; 0/11* 100%; 11/11*
Operator no. 3 11%; 3/27* 89%; 24/27*
Operator no. 4 17%; 1/6* 83%; 5/6*
Operator no. 5 7.5%; 4/53* 93%; 49/53*
*Refers to the number of procedures performed by the given operator; DDD — dual-chamber pacemaker; CRT — cardiac resynchronization 
therapy; ICD — implantable cardioverter defibrillator; VVI — ventricular single-chamber pacemaker
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developing PE after CIED implantation were 
more often on antiplatelet therapy than patients 
without PE after intervention. Tompkins et al. [29] 
demonstrated that bleeding risk is significantly 
higher for patients on dual antiplatelet therapy 
undergoing PPM or ICD implantation and slightly 
higher for patients receiving acetylsalicylic acid 
alone. In the present study, patients with post-
procedural PE more often received dual antiplatelet 
therapy than patients without this complication, 
although this difference did not reach statistical 
significance. There was no significant difference 
in the prevalence of post-procedural PE between 
patients with and without single antiplatelet or 
anticoagulant treatment, however, this might be 
related to a relatively small sample size. Still, 
patients with PE had lower hemoglobin concentra-
tion at baseline. In several previous studies, low 
hemoglobin concentration proved an independent 
predictor of bleeding, including bleeding complica-
tions after cardiac procedures [30, 31]. Importantly, 
in patients who did develop PE after implantation, 
only a trivial amount of fluid was observed, with no 
clinical consequences.
Limitations of the study
The present study has several limitations. 
First, it is a single-center study, including (thus far) 
a relatively small cohort of patients. However, the 
final number of patients in the study will exceed 
400. Secondly, as presented in Figure 1, a large 
number of patients after first CIED implantation 
were not eligible for inclusion, mainly due to 
missing data on pre-implantation echocardiogram. 
Thirdly, echocardiographic assessment is limited to 
the early post-implantation period, without long-
term follow-up. Lastly, this study is a retrospective 
analysis of medical records, and thus, allows only an 
approximate estimation of new post-implantation 
TR and PE incidence. 
Conclusions
Preliminary data suggests that CIED implanta-
tion may lead to early development or progression 
of TR in approximately 16% of patients, however, 
in most of them TR was not hemodynamically sig-
nificant. It seems that operator experience might 
be an important risk factor for TR development. PE 
occurred rarely after CIED implantation, and was, 
in all cases, trivial and lead to no clinical sequel. 
Increasing the number of patients in the on-going 
study will enable a more reliable assessment of 
the prevalence and the risk factors of those CIED 
implantation-related complications. Still, the most 
appropriate method to evaluate the true incidence 
of those complications would be to conduct a pro-
spective study.
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